Results 111 to 120 of about 5,710 (181)

Evolocumab-associated haemorrhagic pericarditis with cardiac tamponade: case report. [PDF]

Eur Heart J Case Rep
Kim AY, Bradel L, Hossain N, Wong B.
europepmc   +1 more source

Evolocumab in the treatment of refractory chylothorax induced by systemic lupus erythematosus complicated with hyperlipidemia: a case report and literature review. [PDF]

Front Immunol
Li X, Li A, Tian M, Chen X, Zhao H, Dai Z, Li J, Li C.   +7 more
europepmc   +1 more source

Timing of Evolocumab Initiation After Acute Coronary Syndrome and Long-Term Lipid and Cardiovascular Outcomes: A Multicenter Real-World Cohort Study. [PDF]

Pharmaceuticals (Basel)
Alfehaid L, Habeeb EA, Badawoud AM, Alsuhaibani SA, Almutairi R, Alyahya R, Alquraishi S, Alharbi H, Alshammari S, Alfulayyih H, Almasoud W, Almakrami AA, Almutairi A, Al Yami MS.   +13 more
europepmc   +1 more source

Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. [PDF]

BMC Cardiovasc Disord
Yao J, Sun Q, Liu D, Lin J, Wang W.
europepmc   +1 more source

The Impact of PCSK9 Inhibitors on Circulatory Inflammation: Mechanisms, Evidence, and Application Prospects. [PDF]

JACC Asia
Bing-Yan D, Jing-Ya W, Yu-Juan Y, Xiang-Yu D, Hong-Mei L, Hui P, Yi-Ning Y, Xiao-Lin Y.   +7 more
europepmc   +1 more source

Real-World Low-Density Lipoprotein Cholesterol Control After Transitioning From Evolocumab to Inclisiran. [PDF]

Circ Rep
Tabata T, Chinen T, Nakamura K.
europepmc   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

The effect of PCSK9 inhibitors on cardiovascular outcomes in diabetic patients: a narrative review. [PDF]

Front Pharmacol
Khalid Sharafeldin AB, Aljundi NET, Hussain A, Alaraibi AJ, Butler AE.   +4 more
europepmc   +1 more source

Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]

JACC Adv
Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY.   +4 more
europepmc   +1 more source

PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications. [PDF]

Transl Neurodegener
Wang JDJ, Teo AYT, Xiao B, Chao Y, Zhou ZD, Tan BJ, Chan LL, Rosalie E, Tan EK.   +8 more
europepmc   +1 more source